Repligen Corporation ($RGEN) Stock Forecast: Up 5.5% Today

What is Repligen Corporation?

Repligen Inc. (NASDAQ: RGEN) is a company that specializes in providing bioprocessing products and technologies to the biopharmaceutical industry. Today, the stock showed a notable upward movement in the market.

Why is Repligen Corporation going up?

RGEN stock is up 5.5% on Nov 21, 2025 18:41

• The rise in RGEN's stock price is possibly a result of favorable investor sentiment towards the company's P/E ratio.
• Despite a slight decline in the previous month, the substantial increase in the stock price over the last year indicates promising long-term growth prospects, which may have attracted investors.
• The 0.65% increase in the current market session could also be influenced by general market positivity or specific industry trends benefiting biopharmaceutical firms like Repligen Inc.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

P/E Ratio Insights for Repligen - Repligen ( NASDAQ:RGEN )

In the current market session, Repligen Inc. ( NASDAQ:RGEN ) share price is at $155.36, after a 0.65% spike. Moreover, over the past month, the stock fell by 1.36%, but in the past year, spiked by 19.66%.

https://www.benzinga.com/insights/news/25/11/49010747/pe-ratio-insights-for-repligen

Trending Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.0% Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

SNDL Inc. ($SNDL) Stock Forecast: Down 5.2% Today

Clear Secure Inc. ($YOU) Stock Forecast: Down 5.3% Today

CoStar Group Inc. ($CSGP) Stock Forecast: Down 5.5% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.6% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

XRP ($XRP) Crypto Forecast: Down 5.0% Today

American Eagle Outfitters Inc. ($AEO) Stock Forecast: Up 5.8% Today

GameStop Corp. ($GME) Stock Forecast: Up 5.4% Today

Repligen Corporation Price History

21.10.2025 - RGEN Stock was up 5.5%

• The rise in RGEN's stock price is possibly a result of favorable investor sentiment towards the company's P/E ratio.
• Despite a slight decline in the previous month, the substantial increase in the stock price over the last year indicates promising long-term growth prospects, which may have attracted investors.
• The 0.65% increase in the current market session could also be influenced by general market positivity or specific industry trends benefiting biopharmaceutical firms like Repligen Inc.

07.04.2025 - RGEN Stock was down 6.5%

• Repligen Corporation's stock, RGEN, exhibited a decline today, possibly attributed to profit-taking by investors following a period of strong growth.
• A comparative analysis between QGEN and RGEN could have triggered uncertainty among investors, leading to the selling pressure on RGEN shares.
• The anticipation surrounding the upcoming investor conferences might have prompted some investors to reassess their positions in RGEN, contributing to the downward trend.
• In summary, today's bearish movement in RGEN could be linked to profit-taking, comparative analysis with QGEN, and investor sentiment around the forthcoming conferences.

22.07.2025 - RGEN Stock was up 5.4%

• The company revealed its involvement in three forthcoming investor conferences, hinting at possible growth prospects.
• Repligen's participation in these conferences could be perceived as a tactic to appeal to more investors and highlight its advancements in bioprocessing technology.
• Investors might interpret Repligen's proactive engagement with the investment community as a vote of confidence in its future potential, potentially attracting more buyers and boosting the stock price.

06.04.2025 - RGEN Stock was down 6.6%

• Despite reporting strong Q1 earnings and raising revenue guidance for 2025, the market may have had higher expectations, resulting in a sell-off.
• Investors might be favoring QIAGEN (QGEN) over Repligen (RGEN) as a more attractive value stock, impacting RGEN's stock price.
• The bearish movement could be due to profit-taking by traders who had bought the stock in anticipation of positive earnings, causing a temporary decline in the stock price.

30.03.2025 - RGEN Stock was down 5.0%

• Despite exceeding expectations in earnings and revenue for Q1, Repligen (RGEN) faced a significant bearish trend in its stock.
• There is a possibility that external factors or guidance provided by the company led to an exaggerated market reaction, resulting in a sell-off.
• Investor apprehension regarding challenges in the biotech industry may have contributed to the negative outlook on Repligen's stock.
• Profit-taking or a general market downturn could have influenced the bearish movement, overshadowing Repligen's positive earnings report.

01.07.2025 - RGEN Stock was down 5.4%

• The stock's downward trend, which has persisted for over 1400 days, may have contributed to the bearish movement.
• While Repligen announced a strategic partnership with Novasign for bioprocessing digitalization, investors appeared more concerned about the long-term downtrend and associated risks.
• Market sentiment appears to have been influenced by technical analysis and Adhishthana principles, signaling ongoing weakness in the stock and leading to today's bearish movement.

17.06.2025 - RGEN Stock was up 5.0%

• Repligen Corporation announced the upcoming release of its second-quarter 2025 financial results, creating anticipation and positive sentiment among investors.
• The market might be reacting positively to the potential growth and performance indicators that could be revealed during the earnings call.
• Investors seem optimistic about Repligen's future prospects, leading to increased buying activity and driving the stock price higher.
• The strong bullish movement could be a reflection of confidence in Repligen's business strategies and financial health, as hinted by the upcoming financial report.

03.05.2025 - RGEN Stock was up 5.2%

• Upward trends are noticeable among options traders for Repligen (RGEN) stock, reflecting a positive market sentiment.
• The increased engagement in the options market implies expectations of favorable updates or progress related to Repligen's operations.
• This upsurge in positive activity may be linked to possible future collaborations, product introductions, or robust financial results, stimulating investor confidence and elevating the stock value.

23.09.2025 - RGEN Stock was up 5.4%

• Despite initial expectations of a decline in Q3 earnings, Repligen (RGEN) demonstrated a strong bullish performance, potentially signaling investor focus on other positive aspects.
• A comparison of Repligen (RGEN) with Alkermes (ALKS) may have contributed to increased investor interest, supporting the upward momentum in the market.
• Market sentiment towards Repligen (RGEN) potentially improved due to factors beyond earnings, such as anticipated growth opportunities or strategic advancements.

29.03.2025 - RGEN Stock was down 5.1%

• Despite Repligen (RGEN) topping Q1 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• The anticipation of a potential beat in the next earnings report might have already been priced into the stock, leading to a sell-off after the strong performance in the previous quarter.
• Investors might be profit-taking after the recent positive surprises, causing a temporary dip in the stock price despite the company's solid financial results.

31.09.2025 - RGEN Stock was up 5.0%

• Despite strong Q3 earnings, with revenue growth surpassing expectations, Repligen (RGEN) witnessed a stock dip possibly due to revised EPS guidance.
• The current bullish market trend for RGEN implies a reevaluation of the initial response to the earnings, indicating a perceived undervaluation of the stock.
• Positive surprises in both earnings and revenues for Q3 may have boosted investor confidence, leading to increased buying activity and a rise in stock price.
• The uptrend in RGEN today may stem from investors revisiting the company's performance and recognizing it as a more appealing investment opportunity, despite the initial setback.

28.09.2025 - RGEN Stock was down 6.0%

• Despite exceeding earnings and revenue forecasts in Q3, Repligen (RGEN) faced a bearish trend, potentially triggering investor sell-off.
• Market sentiment towards Repligen may have been impacted by comparisons with Alkermes (ALKS) in terms of value, contributing to the stock's bearish performance.
• Investors seemed to have responded to the positive earnings results by selling shares to secure profits, resulting in a temporary dip in the stock's value.